MacroGenics
MGNX | NASDAQ
$2.17
-$0.03 (-1.36%)
At close: Nov 16, 2026, 4:00 PM ET
$2.14
-$0.03 (-1.38%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-1.36%
(1D)No price chart data available for 1D timeframe.
Rating
27
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #875/1021 (Top 86%)
Key Statistics
Market Data
Market Cap $138.68M
1D Range
1.94 2.22
52W Range
1.33 4.86
Valuation (TTM)
PE -2.68
PB 5.51
EV/EBITDA 0.94
Valuation (NTM)
Forward PE N/A
Forward PEG -0.06
Price Target $6.00
Cash Flow
FCF Yield -29.8%
SBC Adj. FCF Yield -36.5%
SBC Impact -22.6%
Margins
Gross Margin 4.2%
Operating Margin -70.2%
FCF Margin -36.4%
Growth (CAGR)
Revenue 3Y | 5Y -2.1% |
-0.4%
Dil EPS 3Y | 5Y 31.8% |
22.0%
FCF 3Y | 5Y 11.4% |
13.5%
Returns
ROA -16.2%
ROE -142.2%
ROIC -13.6%
Financial Health
Net Cash
$287.68M
Current Ratio 2.75
Interest Coverage -4.52
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The c...
Sector Healthcare
Industry Biotechnology
Employees 293
IPO Date Oct 10, 2013
Website www.macrogenics.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$0.34
Miss -7.92%
YoY:
-225.93% REV
$18.67M
Miss -52.36%
YoY:
-74.37%Next Earnings
Mar 8, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$6.00
Upside
+176.50%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove MGNX